Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Moderna Therapeutics

This page shows the latest Moderna Therapeutics news and features for those working in and with pharma, biotech and healthcare.

AZ sells stake in Moderna for around $1.2bn

AZ sells stake in Moderna for around $1.2bn

In 2013, AZ invested $240m in Moderna, signing an alliance at the time to discover mRNA therapeutics for cardiometabolic disease and selected oncology targets. ... Moderna Therapeutics’.

Latest news

  • Moderna files record $500m IPO for RNA pipeline Moderna files record $500m IPO for RNA pipeline

    Could be the largest IPO for a biotech start-up. Moderna Therapeutics, a specialist in messenger RNA-based drugs, has filed a $500m initial public offering (IPO) that would break all ... Moderna’s mRNA technology attempts to turn a patient’s own

  • Morning brief: New biotech launched, Merck and Moderna expand collaboration and more Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

    A rapid round up of pharma, biotech and healthcare news. Merck and Moderna expand cancer vaccines work. ... Today brings the latest confirmation of that, with Merck &Co expanding its existing collaboration with Moderna Therapeutics to develop and

  • BMS to explore new options for its immuno-oncology drug Opdivo BMS to explore new options for its immuno-oncology drug Opdivo

    The company will work with PsiOxus Therapeutics to evaluate the safety and efficacy of the Oxford, UK biotech's enadenotucirev in combination with Opdivo for the treatment of a range of ... Like BMS, Merck &Co has also moved to extend the reach of its

  • Merck & Co signs cancer vaccines research deal for Keytruda Merck & Co signs cancer vaccines research deal for Keytruda

    The deal with Moderna Therapeutics will see it use the Cambridge, Massachusetts-based company's novel messenger RNA (mRNA)-based vaccine technology. ... Moderna's mRNA vaccine technology uses the unique mutations present in a patient's tumour to provoke

  • mRNA - message received mRNA - message received

    Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious disease; metabolism. ... Valera LLC (Moderna Therapeutics). Infectious diseases. Merck &Co; Pasteur Institute. No clinical

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Moderna Therapeutics has received $8m of the grant to fund early-stage trials of the vaccine and plans to submit an investigational new drug

  • Deal Watch June 2016 Deal Watch June 2016

    Back to the immuno-oncology theme, near the end of June Merck &Co signed a collaboration agreement with Moderna Therapeutics to use Moderna's mRNA technology to develop personalised cancer vaccines. ... licence. 230. Moderna Therapeutics/ Merck &Co.

  • Deal Watch October 2015 Deal Watch October 2015

    Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290. ... 144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation.  Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast   . ... Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Tony de Fougerolles joins Evox Therapeutics as CEO Tony de Fougerolles joins Evox Therapeutics as CEO

    Oxford, UK-based Evox Therapeutics has appointed its new chief executive officer in the form of Tony de Fougerolles. ... Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.

  • Medicxi appoints former GSK chair Moncef Slaoui Medicxi appoints former GSK chair Moncef Slaoui

    Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.

  • MIT chief financial officer joins Moderna Therapeutics MIT chief financial officer joins Moderna Therapeutics

    US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's

  • PureTech Health appoints chief scientific officer PureTech Health appoints chief scientific officer

    Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.

  • Dr Michael Watson appointed as president of Valera Dr Michael Watson appointed as president of Valera

    Former Sanofi Pasteur policy head joins Moderna Therapeutics firm. Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president. ... Moderna's technology, coupled with its goal to deliver transformative

More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...

Quick links